Protocadherin 1 (PCDH1) Promotes Pancreatic Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition (EMT)...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Pancreatic cancer is a highly metastatic disease with poor prognosis.
• The epithelial-mesenchymal transition (EMT) is a key process in cancer metastasis.
• The role of protocadherin-1 (PCDH1) in pancreatic cancer progression remains unclear.

Purpose of the Study:

• To investigate the role of PCDH1 in pancreatic cancer metastasis.
• To elucidate the mechanisms by which PCDH1 influences EMT and the NF-κB signaling pathway.

Main Methods:

• Bioinformatic analysis of clinical pancreatic cancer specimens to correlate PCDH1 expression with clinicopathological features and prognosis.
• In vitro experiments involving siRNA knockdown and plasmid overexpression of PCDH1 in pancreatic cancer cells.
• Assays including CCK-8, Transwell, Western blot, qRT-PCR, and immunofluorescence to assess cell proliferation, invasion, apoptosis, EMT markers, and NF-κB pathway activation.

Main Results:

• PCDH1 is overexpressed in pancreatic cancer tissues and correlates with higher pathological grade and disease progression.
• PCDH1 knockdown inhibits proliferation, migration, and invasion, while overexpression promotes these processes.
• PCDH1 promotes EMT by suppressing E-cadherin and inducing N-cadherin and vimentin.
• PCDH1 activates the NF-κB pathway, and NF-κB inhibition reverses PCDH1-induced EMT.

Conclusions:

• PCDH1 functions as an oncogene in pancreatic cancer, promoting metastasis.
• PCDH1 facilitates pancreatic cancer cell invasion, migration, and EMT via the NF-κB signaling pathway.
• PCDH1 represents a potential therapeutic target for pancreatic cancer treatment.